Dernières informations Corporate et commerciales

Derniers communiqués

New data reinforce Immunoscore® clinical utility in localized Colon Cancer

  • Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
 Lire la suite

Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center

COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients

HalioDx SAS, the immuno-oncology...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

Mr Gilles Bloch, Président Directeur Général de l’Inserm, remet l’insigne de Chevalier de la Légion d’honneur à Jérôme Galon

HalioDx SAS, la société de diagnostic en immuno-oncologie, a annoncé aujourd'hui que son fondateur scientifique,...

 Lire la suite

Jérôme Galon has been awarded the French the Legion of Honor, or "Legion d'Honneur", received today from Gilles Bloch, Chairman and Chief Executive Officer of Inserm

Lire la suite

HalioDx contribution to precision medicine at ESMO 2020

HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of Medical OncologyV...

 Lire la suite

IMMUNOSCORE® IC in NSCLC

Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer

HalioDx SAS, the immuno-oncology diagnostic company, today announced that it has entered into a Collaboration Agreement...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

Immunoscore® included in ESMO Clinical Practice Guidelines 2020

HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been included in the 2020...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

HalioDx strengthens its Management Team

  • Stephane Debono, EVP, Diagnostics BU and CEO of HalioDx Inc., is appointed Deputy CEO
  • Philippe Mourere joins the...
 Lire la suite

See more Press releases